Optimization of initial tacrolimus dose using pharmacogenetic testing.

E, Thervet; MA, Loriot; S, Barbier; M, Buchler; M, Ficheux; G, Choukroun; O, Toupance; G, Touchard; C, Alberti; Pogamp P, Le; B, Moulin; Meur Y, Le; AE, Heng; JF, Subra; P, Beaune; C, Legendre

doi:10.1038/clpt.2010.17

Public

Optimization of initial tacrolimus dose using pharmacogenetic testing.

Shared by NobleBlocks on Apr 14, 2010 • 12:00 AM UTC

Authors:

Thervet E

Loriot MA

Barbier S

Abstract

Retrospective studies have demonstrated that patients who are expressors of cytochrome P4503A5 (CYP3A5) require a higher tacrolimus dose to achieve a therapeutic trough concentration (C(0)). The aim of this study was to evaluate this effect prospectively by pretransplantation adaptation. We randomly...

Discussions